[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

U.S. Cardiac Resynchronization Therapy Market by Type (CRT Pacemaker and CRT Defibrillator), Application (Intraventricular Dyssynchrony, Interventricular Dyssynchrony, and Atrioventricular Dyssynchrony), and End User (Hospitals, Ambulatory Surgical Centers, and Specialized Cardiac Treatment Centers): Opportunity Analysis and Industry Forecast, 2020–2027

February 2021 | 109 pages | ID: U6311A802286EN
Allied Market Research

US$ 3,648.00

E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027.

Cardiac resynchronization therapy (CRT) is a treatment prescribed to help heart beat with the correct rhythm. CRT uses a pacemaker for restoration of the normal timing pattern of heartbeat. It is a procedure to implant a device in the chest to make heart's chambers contract proficiently. Cardiac resynchronization therapy is traditionally a treatment for patients who experience heart failure and then develop an arrhythmia. Cardiac resynchronization therapy offers applications in the intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony.

Surge in geriatric population along with rise in prevalence of cardiovascular diseases (CVDs), increase in technological advancements in the CRT pacemakers and CRT defibrillators, and rise in healthcare expenditure in the U.S. are some of the major factors that boost the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), it is estimated that 12.1 million individuals will have atrial fibrillation (AFib) by 2030 in the U.S. In addition, the CDC reported that approximately 6.2 million adults in the U.S. are suffering from heart failure. One patient dies every 36 seconds in the U.S. from cardiovascular disease. Heart disease is the leading cause of death for men, women, and individuals of most racial and ethnic groups in the U.S. In addition, about 655,000 Americans die from heart disease every year, which is one in every four deaths.

In contrast, the presence of stringent regulations for CRT devices and high cost of CRT therapy in the U.S. are anticipated to impede the market growth over the assessment period.

The U.S. cardiac resynchronization therapy market is segmented into type, application, and end user. By type, the market is categorized into CRT pacemaker and CRT defibrillator. Pacemaker is a small electronic device, implanted below the collarbone and are connected to the heart with wires or leads to the right chambers of the heart. The CRT defibrillator segment is expected to dominate the market over the forecast period due to rising adoption of CRT defibrillators over CRT pacemakers and the launch of technologically advanced CRT defibrillators.

On the basis of application, the U.S. cardiac resynchronization therapy market is divided into intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony. Intraventricular dyssynchrony is the principal factor responsible for contractile dysfunction, the one most affected by and most predictive of response to resynchronization therapy. The intraventricular dyssynchrony segment spearheaded the market in 2019 in terms of revenue attributed to comparatively higher incidence of intraventricular dyssynchrony among patients with heart failure and left bundle branch block. Interventricular dyssynchrony refers to the discordance between the times of right ventricular (RV) and left ventricular (LV) contraction, or delay in segmental wall motion. Atrioventricular (AV) dyssynchrony occurs when there is an unfavorable difference in timing between atrial and ventricular contractions. It is a delay in the normal sequential AV contraction, due to delayed conduction through the AV node. This refers to abnormal timing of contraction of the left atrium (LA) with respect to the LV impairs cardiac function.

By end user, the U.S. cardiac resynchronization therapy market is segregated into hospitals, ambulatory surgical centers, and specialized cardiac treatment centers. The hospitals segment is anticipated to lead the market throughout the forecast period owing to higher number of CVDs performed along with rise in adoption of cardiac resynchronization therapy devices in the hospital settings. On the other hand, the specialized cardiac treatment centers segment is expected to witness significant market outlook during the study period as it provides diagnostic and treatment services for patients suffering from heart diseases with the assistance of an integrated medical team.

The cardiac resynchronization therapy market is highly competitive in nature, as major players in this vertical are concentrating on growth strategies such as product launches, mergers and acquisitions (M&As), partnerships and collaborations to gain competitive advantage. For instance, in June 2018, MicroPort Scientific Corporation received approval by the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for PLATINIUM 4LV SonR CRT-D cardiac resynchronization device and the associated SonRtip lead featuring the innovative SonR technology. The SonR system uses an innovative contractility micro-sensor embedded in the SonRtip lead to assess the patient's left ventricular contractility and optimize the cardiac resynchronization therapy response in heart failure patients.

The key players operating in the U.S. cardiac resynchronization therapy market include Medtronic plc, Abbott Laboratories, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Lepu Medical Technology (Beijing) Co., Ltd., LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Osypka Medical GmbH.

KEY BENEFITS FOR STAKEHOLDERS
      • The study provides an in-depth analysis of the U.S. cardiac resynchronization therapy market size along with the current trends and future estimations to elucidate the imminent investment pockets
              • It offers market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
      • A comprehensive analysis on country assists to understand the country market and facilitate the strategic business planning and determine prevailing opportunities
      • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the U.S. cardiac resynchronization therapy market growth
KEY MARKET SEGMENTS

By Type
  • CRT Pacemaker
  • CRT Defibrillator
By Application
  • Intraventricular Dyssynchrony
  • Interventricular Dyssynchrony
  • Atrioventricular Dyssynchrony
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Cardiac Treatment Centers
List of key players profiled in the report
  • Medtronic plc
  • Abbott Laboratories
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • LivaNova PLC
  • MEDICO S.p.A.
  • MicroPort Scientific Corporation
  • OSCOR Inc.
  • Osypka Medical GmbH
List of other players in the value chain (profiles not included in the report):
  • Cook Group Incorporated
CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
  1.4.1.Secondary research
  1.4.2.Primary research
  1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings
  3.2.1.Top investment pockets
  3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Market dynamics
  3.4.1.Drivers
    3.4.1.1.Surge in geriatric population along with rise in prevalence of cardiovascular diseases
    3.4.1.2.Technological advancements in the CRT devices
    3.4.1.3.Surge in healthcare infrastructure in the U.S.
  3.4.2.Restraints
    3.4.2.1.High cost of CRT devices
    3.4.2.2.Product recalls in the U.S.
    3.4.2.3.Shortage of healthcare professionals in U.S.
  3.4.3.Opportunity
    3.4.3.1.Emerging opportunities in the low economic U.S. states
  3.4.4.Impact analysis
3.5.Impact analysis of COVID-19 on the cardiac resynchronization therapy market

CHAPTER 4:U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY TYPE

4.1.Overview
  4.1.1.Market size and forecast, by type
4.2.CRT pacemaker
  4.2.1.Market size and forecast
4.3.CRT defibrillator
  4.3.1.Market size and forecast

CHAPTER 5:U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY APPLICATION

5.1.Overview
  5.1.1.Market size and forecast, by application
5.2.Intraventricular dyssynchrony
  5.2.1.Market size and forecast
5.3.Interventricular dyssynchrony
  5.3.1.Market size and forecast
5.4.Atrioventricular dyssynchrony
  5.4.1.Market size and forecast

CHAPTER 6:U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY END USER

6.1.Overview
  6.1.1.Market size and forecast , by end user
6.2.Hospitals
  6.2.1.Market size and forecast
6.3.Ambulatory surgical centers
  6.3.1.Market size and forecast
6.4.Specialized cardiac treatment centers
  6.4.1.Market size and forecast

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES
  7.1.1.Company overview
  7.1.2.Company snapshot
  7.1.3.Operating business segments
  7.1.4.Product portfolio
  7.1.5.Business performance
  7.1.6.Key strategic moves and developments
7.2.BOSTON SCIENTIFIC CORPORATION
  7.2.1.Company overview
  7.2.2.Company snapshot
  7.2.3.Operating business segments
  7.2.4.Product portfolio
  7.2.5.Business performance
  7.2.6.Key strategic moves and developments
7.3.BIOTRONIK SE & CO. KG
  7.3.1.Company overview
  7.3.2.Company snapshot
  7.3.3.Operating business segments
  7.3.4.Product portfolio
  7.3.5.Key strategic moves and developments
7.4.LIVANOVA PLC
  7.4.1.Company overview
  7.4.2.Operating business segments
  7.4.3.Product portfolio
  7.4.4.Business performance
7.5.LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
  7.5.1.Company overview
  7.5.2.Company snapshot
  7.5.3.Operating business segments
  7.5.4.Product portfolio
7.6.MEDTRONIC PLC
  7.6.1.Company overview
  7.6.2.Company snapshot
  7.6.3.Operating business segments
  7.6.4.Product portfolio
  7.6.5.Business performance
  7.6.6.Key strategic moves and developments
7.7.MICROPORT SCIENTIFIC CORPORATION
  7.7.1.Company overview
  7.7.2.Company snapshot
  7.7.3.Operating business segments
  7.7.4.Product portfolio
  7.7.5.Business performance
  7.7.6.Key strategic moves and developments
7.8.MEDICO S.P.A.
  7.8.1.Company overview
  7.8.2.Company snapshot
  7.8.3.Operating business segments
  7.8.4.Product portfolio
7.9.OSCOR INC.
  7.9.1.Company overview
  7.9.2.Company snapshot
  7.9.3.Operating business segments
  7.9.4.Product portfolio
7.10.OSYPKA MEDICAL GmbH
  7.10.1.Company overview
  7.10.2.Company snapshot
  7.10.3.Operating business segments
  7.10.4.Product portfolio

LIST OF TABLES

TABLE 01.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 02.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 03.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 04.ABBOTT: COMPANY SNAPSHOT
TABLE 05.ABBOTT: OERATING SEGMENT
TABLE 06.ABBOTT: PRODUCT PORTFOLIO
TABLE 07.BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 08.BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 09.BOSTON SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 10.BIOTRONIK: COMPANY SNAPSHOT
TABLE 11.BIOTRONIK: OPERATING SEGMENTS
TABLE 12.BIOTRONIK: PRODUCT PORTFOLIO
TABLE 13.LIVANOVA: COMPANY SNAPSHOT
TABLE 14.LIVANOVA: OPERATING SEGMENT:
TABLE 15.LIVANOVA: PRODUCT PORTFOLIO
TABLE 16.LEPU MEDICAL: COMPANY SNAPSHOT
TABLE 17.LEPU MEDICAL: OPERATING SEGMENTS
TABLE 18.LEPU MEDICAL: PRODUCT PORTFOLIO
TABLE 19.MEDTRONIC: COMPANY SNAPSHOT
TABLE 20.MEDTRONIC: OPERATING SEGMENTS
TABLE 21.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 22.MICROPORT: COMPANY SNAPSHOT
TABLE 23.MICROPORT: OPERATING SEGMENTS
TABLE 24.MICROPORT: PRODUCT PORTFOLIO
TABLE 25.MEDICO: COMPANY SNAPSHOT
TABLE 26.MEDICO: OPERATING SEGMENTS
TABLE 27.MEDICO: PRODUCT PORTFOLIO
TABLE 28.OSCOR: COMPANY SNAPSHOT
TABLE 29.OSCOR: OERATING SEGMENT
TABLE 30.OSCOR: PRODUCT PORTFOLIO
TABLE 31.OSYPKA MEDICAL: COMPANY SNAPSHOT
TABLE 32.OSYPKA MEDICAL: OPERATING SEGMENTS
TABLE 33.OSYPKA MEDICAL: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020
FIGURE 06.LOW BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.IMPACT ANALYSIS
FIGURE 12.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR CRT PACEMAKER, 2019-2027 ($MILLION)
FIGURE 13.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR CRT DEFIBRILLATOR, 2019-2027 ($MILLION)
FIGURE 14.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR INTRAVENTRICULAR DYSSYNCHRONY, 2019-2027 ($MILLION)
FIGURE 15.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR INTERVENTRICULAR DYSSYNCHRONY, 2019-2027 ($MILLION)
FIGURE 16.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR ATRIOVENTRICULAR DYSSYNCHRONY, 2019-2027 ($MILLION)
FIGURE 17.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR HOSPITALS, 2019-2027 ($MILLION)
FIGURE 18.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR AMBULATORY SURGICAL CENTERS, 2019-2027 ($MILLION)
FIGURE 19.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR SPECIALIZED CARDIAC TREATMENT CENTERS, 2019-2027 ($MILLION)
FIGURE 20.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 21.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 22.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 23.BOSTON SCIENTIFIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.BOSTON SCIENTIFIC: NET SALES, BY SEGMENT, 2019 (%)
FIGURE 25.BOSTON SCIENTIFIC: NET SALES, BY REGION, 2019 (%)
FIGURE 26.LIVANOVA: NET SALES, 2017-2019 ($MILLION)
FIGURE 27.LIVANOVA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.LIVANOVA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.MEDTRONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.MEDTRONIC: REVENUE SHARE BY CARDIAC RHYTHM & HEART FAILURE SEGMENT, 2020 (%)
FIGURE 32.MEDTRONIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.MICROPORT: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.MICROPORT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.MICROPORT: REVENUE SHARE, BY REGION, 2019 (%)


More Publications